Plerixafor can be used to mobilize successfully autologous stem cells in patients who have failed traditional mobilization techniques. 1 It has also been used in pilot studies in normal donors to mobilize sufficient stem cells to allow transplantation. 2 We recently used it in a normal donor who failed to mobilize adequate numbers of stem cells with G-CSF.
A 56-year-old woman was identified as a normal donor for her HLA-matched sibling. Her history was unremarkable except for controlled depression and anxiety. Baseline blood count was normal: WBC 6.1 Â 10 9 per liter, Hb 12.8 g per 100 mL and platelets 195 Â 10 9 per liter. PTT was elevated and an incidental diagnosis of a lupus anticoagulant was carried out. Her weight was 42 kg and the recipient weighed 75 kg.
She received 10 mg/kg G-CSF s.c. daily per our standard protocol. On the fifth day of G-CSF, she underwent large volume leukapheresis (18l) on a Cobe Specta cell separator (Gambro, Lakewood, CO, USA) by a temporary central line. At the time of collection, her WBC count was 50.6 Â 10 9 per liter. Only 0.35 Â 10 6 CD34 þ cells per kg recipient weight could be collected. The second day of collection led to even poorer numbers, and the total after 2 days was 0.49 Â 10 6 CD34 þ cells per kg (Table 1) . She received a second dose of G-CSF that afternoon and a dose of plerixafor 0.24 mg/kg at 2000 hours. The following morning, she underwent her third collection and was able to yield an additional 1.52 Â 10 6 CD34 þ cells per kg. There were no adverse effects noted from the plerixafor or the additional dose of G-CSF.
The recipient who had already received the conditioning regimen (BU/CY) received GVHD prophylaxis with CYA and mini-MTX. Neutrophil count reached 0.5 Â 10 9 per liter on day 23 and platelet count reached 20 Â 10 9 per liter on day 29.
Although the incidence of stem cell mobilization failure in normal donors is low, there are limited data on the overall incidence. Up to 4% of donors may provide insufficient cells to proceed to transplantation. [3] [4] [5] [6] [7] Factors that may increase the risk of mobilization failure include older age, female gender, low baseline WBC count and low donor weight.
Because patients have already received ablative therapy by the time donor cells are collected in most centers, the lack of availability of adequate stem cells is a significant problem. Options in donors who have failed collection with standard mobilization techniques include increased doses or combinations of growth factors or a BM collection.
There are difficulties with these approaches. Efforts to increase the doses or to add more growth factors take an additional 3-4 days-delaying stem cell infusion. Subsequent collections are typically low yield as well. This additional period of pancytopenia may be dangerous. A BM collection can be performed (this was our back-up plan). However, often these do not yield significantly more cells in patients who fail apheresis and place the donor at risk of anesthesia.
Plerixafor allows mobilization in patients with malignant diseases who have failed previous attempts at mobilization 1 and increases stem cell yields in patients with myeloma and NHL compared to G-CSF. 8, 9 It has been used to collect stem cells from normal donors, 2 and after failure of BM collection 10 but to the best of our knowledge this is the first example of its use following failure to collect adequate stem cells from an apheresis product.
The use of plerixafor using the 'just in time' rescue strategy allowed us to collect sufficient cells for transplant with only a 1-day delay. We believe the addition of plerixafor in normal allogeneic donors who are poor mobilizers should be considered as an option. It can minimize delays in collection and avoid potential complications of anesthesia. 
